LKB1

Young Investigators awarded $200k to study innovative new ways to engage the body’s immune system to fight lung cancer

Retrieved on: 
Monday, January 17, 2022
Research, Patient, Treatment of lung cancer, Presidential Young Investigator Award, Mortality, CA, GLOBE, Bristol Myers Squibb, Lung cancer, Roy Castle Lung Cancer Foundation, LKB1, Immune system, Neoplasm, Immunotherapy, LCFA, Uranium, Pharma, Young

Los Angeles, CA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Two new $200,000 grant-funded studies supported by the Lung Cancer Foundation of America, the International Lung Cancer Foundation, and generously funded in part by Bristol-Myers Squibb , are investigating ways to harness the bodys powerful immune system to better treat lung cancer.

Key Points: 
  • Los Angeles, CA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Two new $200,000 grant-funded studies supported by the Lung Cancer Foundation of America, the International Lung Cancer Foundation, and generously funded in part by Bristol-Myers Squibb , are investigating ways to harness the bodys powerful immune system to better treat lung cancer.
  • Dr. Salehi-Rad is a lung cancer researcher studying the effects of a novel lung cancer vaccine that uses modified cells from the patients own tumor.
  • The International Lung Cancer Foundation aims to accelerate the pace of thoracic malignancy research, to inspire researchers to focus their careers on lung cancer, and to reduce the worldwide lung cancer mortality rate.
  • Lung Cancer Foundation of America is leading the fight against lung cancer through funding innovative and transformative lung cancer research.

Endeavor BioMedicines Licenses ULK1/2 Inhibitor Program from Salk Institute and Sanford Burnham Prebys to Broaden Its Precision Oncology Pipeline

Retrieved on: 
Thursday, September 16, 2021
Science, Other Science, Biotechnology, Research, Oncology, Health, Clinical Trials, Other Health, Nutrient, Standard of care, Cosford, Precision medicine, Program, Idiopathic pulmonary fibrosis, Cancer, Sanford Burnham Prebys Medical Discovery Institute, Biology, Drug discovery, CEO, Drug resistance, Technology, Facebook, Health, Diabetes, Immunology, Patient, Institute, Autophagy, Laboratory, Genetics, Fibrosis, Salk Institute for Biological Studies, NCI, IND, Entrepreneurship, Alvin J. Siteman Cancer Center, Neoplasm, Disease, LKB1, Large-cell lung carcinoma, Cell biology, Ageing, Dream, KRAS, Biomedical Research, Recycling, Face, Nature, Lung, Research, Neuroscience, Oncogene, Pharmaceutical industry

Endeavor BioMedicines , a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases including oncology and fibrosis, today announced the in-licensing of a ULK1/2 inhibitor program from the Salk Institute for Biological Studies and Sanford Burnham Prebys.

Key Points: 
  • Endeavor BioMedicines , a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases including oncology and fibrosis, today announced the in-licensing of a ULK1/2 inhibitor program from the Salk Institute for Biological Studies and Sanford Burnham Prebys.
  • Endeavor plans to complete IND-enabling studies and advance the program into the clinic initially in colorectal and lung cancers in the next 18 months.
  • These patients are generally resistant to the standard of care (chemotherapy or immuno-oncology treatment) and face a very poor prognosis.
  • Endeavor BioMedicines is a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases, including oncology and fibrosis.